European Scientific Cooperative on Phytotherapy

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

Retrieved on: 
onsdag, september 20, 2023
Vaccine, Infection, National Institute of Allergy and Infectious Diseases, European Scientific Cooperative on Phytotherapy, Antigen, Cleveland Clinic, Human, Biotechnology, Vaccination, PDSB, Ferret, NG2, HAI, Weight loss, H3N2, Doctor of Philosophy, Mock, Protein, CD8, Animal, PDS, MD, CD4, Conference, COBRA, H1N1

“We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.

Key Points: 
  • “We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.
  • In addition to active neutralization of various influenza strains, the data demonstrated that PDS0202 prevented illness, weight loss and importantly protected the lungs of vaccinated animals from H1N1,” said Dr. Ross.
  • PDS0202 combines PDS Biotech’s Infectimune® novel investigational immune activating platform with proprietary Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens.
  • This robust immune response to the COBRA antigens suggests strong potential for PDS0202 as a broad and long-term protecting universal influenza vaccine.

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

Retrieved on: 
tisdag, september 19, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Vaccine, Infection, European Scientific Cooperative on Phytotherapy, Diversified Specialty Institute Holdings, Inc., Influenza, Omicron, AE, Vaccination, SARS-CoV-2, Nephrology, SARS-CoV-2 Omicron variant, Public, Aes, Hereditary angioedema, Drug, Haemophilia, ARCT, CSL, Cell, RNA, Delta, Messenger, HAE, Iron deficiency, Patient, Beta, Liver, Poster, Immunodeficiency, Conference, North West Ambulance Service, B.1, Arcturus

Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.

Key Points: 
  • Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.
  • However, sa-mRNA also provides the body with instruction to make copies of the mRNA, amplifying the amount of protein made.
  • This advanced technology has shown the potential to offer longer duration of immune response at considerably lower doses compared to conventional mRNA vaccines.
  • Similar trends were observed for other SARS-CoV-2 variants including Beta, Delta, Omicron BA.1, Omicron BA.2, and Omicron BA.4/5.

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

Retrieved on: 
måndag, september 18, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, European Scientific Cooperative on Phytotherapy, Influenza, Medical Affairs Bureau, MHLW, SARS-CoV-2, Head, Kidney, Ministry of Health, Labour and Welfare, Fast Track, Research, COVID, Ministry, Ensitrelvir, Patient, Risk, Hearing, Ministry of Health (Saudi Arabia), BMI, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Cancer, Food, Kidney disease, Pharmaceutical industry, Vaccine, Shionogi

Ensitrelvir is an investigational oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

Key Points: 
  • Ensitrelvir is an investigational oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
  • Known as Xocova® in Japan, ensitrelvir received emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of SARS-CoV-2 infection in November 2022.
  • In April 2023, ensitrelvir was granted Fast Track designation by the U.S. Food and Drug Administration.
  • “These results indicate the potential for ensitrelvir to help address these needs.”

CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems

Retrieved on: 
tisdag, september 19, 2023
European Scientific Cooperative on Phytotherapy, Centre de coopération internationale en recherche agronomique pour le développement, Public, RCT, Season, ASX, CSL, Research, Science, Influenza, Patient, Risk, Randomized controlled trial, Disease, RWE, Mortality, Vaccine, Conference, Pneumonia

SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today shared new real-world evidence (RWE) studies conducted in the United States, demonstrating the value of influenza vaccination in protecting public health.

Key Points: 
  • SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today shared new real-world evidence (RWE) studies conducted in the United States, demonstrating the value of influenza vaccination in protecting public health.
  • These data are being presented at oral and poster sessions at the European Scientific Working Group on Influenza (ESWI) Conference taking place in Valencia, from September 17-20, 2023.
  • "At CSL Seqirus, we are committed to advancing the science of influenza prevention, and these studies show the benefits of innovative vaccine technologies, including cell-based and adjuvanted influenza vaccine technology, on reducing the burden of flu."
  • RWE is a complement to randomized controlled trial (RCT) research, assessing influenza vaccine effectiveness on a continual basis and providing an ever-growing data set on real-world outcomes.

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Retrieved on: 
måndag, september 18, 2023
Vaccine, European Scientific Cooperative on Phytotherapy, Vaccination, COVID-19, ASX, CSL, Infection, Doctor of Philosophy, Intensive care medicine, Death, Influenza, Hospital, ICU, Conference

The Belgian data highlights how adjuvanted vaccines would not only be cost-effective but could also prevent 6,920 influenza infection, 530 hospitalizations and 66 deaths annually.2

Key Points: 
  • The Belgian data highlights how adjuvanted vaccines would not only be cost-effective but could also prevent 6,920 influenza infection, 530 hospitalizations and 66 deaths annually.2
    SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal influenza on hospitals and broader healthcare systems.1,2 These data are being presented in poster sessions at the European Scientific Working Group on Influenza (ESWI) Conference taking place in Valencia, from 17-20 September 2023.
  • "In a world where healthcare systems are laser-focused on enhancing the prevention of infectious diseases, vaccination isn't just an option but an essential tool," said Joaquin Mould-Quevedo, PhD, Global HEOR & Value Strategy Director, CSL Seqirus.
  • "As a global leader in influenza protection, CSL Seqirus recognizes its responsibility to help reduce the burden of flu around the world, and data presented at ESWI provide insight into how enhanced influenza vaccines might ease that burden on French and  Belgian health systems and communities.
  • "1,2
    In France, approximately 2 to 6 million individuals are affected by influenza annually, leading to over 20,000 hospitalizations and 10,000 excess deaths, 90% of which occur in older adults.1 A new analysis spotlights how influenza vaccines can offer a powerful prevention tool that reduces healthcare resource use.1 Findings from a dynamic transmission model indicated that standard-dose quadrivalent influenza vaccines for this demographic could reduce hospitalizations  by 11.1%-30.0% and ICU admissions  by 9.7%-28.7%.1 Additionally, enhanced vaccines are projected to further reduce the strain on hospitals and intensive care units by 10-15%, supporting bed availability during a potential COVID-19 endemic wave.1
    In Belgium, where roughly 62% of older adults received a standard-dose egg-based influenza vaccine between 2015-2019, an analysis was conducted to investigate the potential cost effectiveness of using an adjuvanted quadrivalent influenza vaccine (aQIV).2 Findings from the analysis, based on a static cost-effectiveness model, showed that transitioning to aQIV could prevent 6,920 influenza infections a year that would typically seek medical care, along with 530 hospitalizations and 66 deaths.2 From a cost perspective, aQIV was both cost-effective with an incremental cost of €15,227/QALY when compared to the standard dose and cost-saving compared with the high-dose vaccine.2

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Retrieved on: 
söndag, september 17, 2023
Biotechnology, COVID-19, Health, Pharmaceutical, Clinical Trials, Viral, Medication, European Scientific Cooperative on Phytotherapy, Oral, Correlation, RSV, Palacio de Congresos, Conference, Treatment, Vaccine, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.
  • Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity”

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

Retrieved on: 
onsdag, september 6, 2023
Vaccine, European Scientific Cooperative on Phytotherapy, Biotechnology, PDSB, Ferret, Infection, H3N2, Protein, Conference, COBRA

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that data from preclinical studies in ferrets of PDS0202, the company’s universal influenza vaccine utilizing proprietary COBRA (computationally optimized broadly reactive antigen) hemagglutinin (HA) flu proteins, will be featured in an oral lecture at the European Scientific Working Group on Influenza (ESWI) Conference.

Key Points: 
  • PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that data from preclinical studies in ferrets of PDS0202, the company’s universal influenza vaccine utilizing proprietary COBRA (computationally optimized broadly reactive antigen) hemagglutinin (HA) flu proteins, will be featured in an oral lecture at the European Scientific Working Group on Influenza (ESWI) Conference.
  • ESWI is being held September 17-20, 2023, in Valencia, Spain.
  • Abstract Title: Influenza pre-immune ferrets vaccinated with computationally optimized recombinant HA proteins generate sero-protective antibody responses against H1N1 and H3N2 viruses from the last decade.

Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

Retrieved on: 
tisdag, december 7, 2021
AIM, Synairgen, Company, COPD, LSE, MX1, University of Southampton, Gene expression, Conference, Drug discovery, European Scientific Cooperative on Phytotherapy, Food, Gamma, Patient, Inhalation, IFN, VOC, Alpha, Immortalised cell line, Chronic obstructive pulmonary disease, NIHR, Asthma, National Institute, Multimedia, COVID-19, University, Biomarker, Sputum, Interferon, National Institute for Health Research, FDA, Infection, OAS1, Poster, Cell, Severe acute respiratory syndrome coronavirus 2, US Foods, Vaccine, Medical device, Pharmaceutical industry

Synairgen is investigating the in vitro activity of SNG001 against the Delta and Omicron variants of SARS-CoV-2 and will make data available as soon as possible.

Key Points: 
  • Synairgen is investigating the in vitro activity of SNG001 against the Delta and Omicron variants of SARS-CoV-2 and will make data available as soon as possible.
  • "SNG001 is an investigational drug currently in Phase 3 trials, with the first data read out early in 2022, and contains the essential antiviral protein interferon beta, a protein that 'switches on' antiviral defences.
  • We presented data showing that SNG001 activates the lungs' antiviral defences for 24 hours after a dose has been delivered, supporting our once-a-day dosing schedule,"Dr Monk added.
  • The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs.

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

Retrieved on: 
tisdag, december 7, 2021
RWE, Risk, Influenza vaccine, Population, Hospital, Disease, CSL, Haemophilia, European Scientific Cooperative on Phytotherapy, Economy, VAERS, Vaccine, CSL Behring, Antibody, Muscle weakness, Allergy, World, Event-driven architecture, Health, Influenza, Patient, Life expectancy, Selection bias, ASX, MF59, Conference, CDC, World Health Organization, Pablo de Olavide University, R, Season, Ageing, Society, FDA, Vaccination, TIV, Guillain–Barré syndrome, Degenerative disease, Research, Biotechnology, Immune system, MD, Immunodeficiency, Neve Ativ, WHO, Health insurance, Pharmaceutical industry, Dietary supplement

Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.

Key Points: 
  • Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
  • FLUAD (Influenza Vaccine, Adjuvanted) and FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted)
    What are FLUAD and FLUAD QUADRIVALENT?
  • To learn more, talk about FLUAD and/or FLUAD QUADRIVALENT with your healthcare provider or pharmacist.

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021

Retrieved on: 
måndag, december 6, 2021
Patient, Private Securities Litigation Reform Act, United States Medical Licensing Examination, Security (finance), Leiden University Medical Center, U.S. Securities and Exchange Commission, Ophthalmology, Safety, Molecular Partners, Half-life, Risk, CEO, Conference, PK, Company, Novartis, Hospital, Form, Clinical trial, SEC, Pharmacokinetics, Investor, Department, Therapy, COVID-19, European Scientific Cooperative on Phytotherapy, Omicron, Infection, Corporate Affairs, CHDR, Twitter, GLOBE, Marketing, Partner, Molecule, LUMC, NASDAQ, Pharmaceutical industry

The single arm Phase 2a study enrolled 12 patients, all of whom were confirmed as positive for COVID-19 with mild to moderate symptoms.

Key Points: 
  • The single arm Phase 2a study enrolled 12 patients, all of whom were confirmed as positive for COVID-19 with mild to moderate symptoms.
  • The single center study was designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep.
  • These data further support ensovibeps potential as a valuable treatment option for COVID-19 patients and we look forward to reviewing the results from the ongoing, global Phase 2-3 trial, EMPATHY.
  • Molecular Partners collaboration partner, Novartis, is conducting the clinical trial for ensovibep, with Molecular Partners as a sponsor.